Non-pharmacological Management 2011 Update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the Prevention, Detection and Management of Chronic Heart Failure in Australia, 2006 Provides Current Clinical Guidance on Chf

Chronic heart failure (CHF) is a complex and lethal clinical syndrome accounting for an increasing number of Australian hospital separations and more than 2700 Australian deaths in 2008. In 2006, the National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand published Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. Results from recently published clinical trials provide additional information to be considered in the prevention, detection and management of CHF. In some cases, this new evidence strengthens recommendations previously made in the 2006 guidelines; in others, it provides new approaches to current recommended practice. Areas in which there have been significant new developments include: ➢Use of B‐type natriuretic peptide (BNP) or N‐terminal proBNP plasma level measurement in guiding treatment of CHF ➢New pharmacological approaches to the treatment of systolic heart failure ➢Drugs to avoid or use with caution in CHF ➢Treatment of cardiac arrhythmias in patients with CHF ➢Multidisciplinary care and post‐discharge management programs. While patient circumstances and clinical judgement should guide the interpretation of these findings in the clinical context, this update, together with the 2006 guidelines, provides current clinical guidance on CHF.

[1]  Stefano Ghio,et al.  Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. , 2008, Journal of the American College of Cardiology.

[2]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[3]  H. Krumholz,et al.  Telemonitoring in patients with heart failure. , 2010, The New England journal of medicine.

[4]  A. Cohen-Solal,et al.  Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.

[5]  C. Frampton,et al.  N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. , 2009, Journal of the American College of Cardiology.

[6]  A. Camm,et al.  Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure , 2009 .

[7]  A. L. Waldo Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure , 2009 .

[8]  M. Packer Revive Ii: Multicenter Placebo-controlled Trial of Levosimendan on Clinical Status in Acutely Decompensated Heart Failure , 2005 .

[9]  B. Massie,et al.  Levosimendan Reduces Length of Initial Hospital Stay: The REVIVE II Study , 2006 .

[10]  Peter Buser,et al.  BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. , 2009, JAMA.

[11]  B. Billah,et al.  B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. , 2010, Archives of internal medicine.

[12]  J. Nicholl,et al.  Noninvasive ventilation in acute cardiogenic pulmonary edema. , 2008, The New England journal of medicine.

[13]  J. Schroeder,et al.  Effects of Cardiac Resynchronization on Disease Progression in Patients With Left Ventricular Systolic Dysfunction, an Indication for an Implantable Cardioverter-Defibrillator, and Mildly Symptomatic Chronic Heart Failure , 2004, Circulation.

[14]  R. Fernandez,et al.  Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis. , 2005, JAMA.

[15]  Z. Gąsior,et al.  Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study , 2005, European journal of heart failure.

[16]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[17]  M. Pfeffer,et al.  Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON) , 2003, European journal of heart failure.

[18]  C. Holly Structured telephone support or telemonitoring programmes for patients with chronic heart failure , 2011 .

[19]  P. Ponikowski,et al.  Ferric carboxymaltose in patients with heart failure and iron deficiency. , 2009, The New England journal of medicine.

[20]  A. Morris,et al.  Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus. , 2010, The American journal of cardiology.

[21]  J. Esteve,et al.  Cardiotoxicity of tyrosine-kinase-targeting drugs. , 2010, Cardiovascular & hematological agents in medicinal chemistry.

[22]  John L Sapp,et al.  Cardiac-resynchronization therapy for mild-to-moderate heart failure. , 2010, The New England journal of medicine.

[23]  Christopher M O'Connor,et al.  Coronary bypass surgery with or without surgical ventricular reconstruction. , 2009, The New England journal of medicine.

[24]  A. Cohen-Solal,et al.  Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). , 2009, Journal of the American College of Cardiology.

[25]  V. Hasselblad,et al.  Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. , 2009, American heart journal.

[26]  K. Dickstein,et al.  Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial , 2009, The Lancet.

[27]  D. Tepper,et al.  Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure: the SURVIVE Randomized Trial , 2007 .

[28]  L. Tavazzi,et al.  ect of n-3 polyunsaturated fatty acids in patients with chronic heart failure ( the GISSI-HF trial ) : a randomised , double-blind , placebo-controlled trial , 1980 .

[29]  Wojciech Zareba,et al.  Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.

[30]  N. Freemantle,et al.  Perindopril for elderly people with chronic heart failure: the PEP‐CHF study , 1999, European heart journal.

[31]  David O. Martin,et al.  Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. , 2008, The New England journal of medicine.

[32]  A. Cohen-Solal,et al.  Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. , 2007, JAMA.

[33]  J. McMurray,et al.  Increased mortality after dronedarone therapy for severe heart failure. , 2008, The New England journal of medicine.

[34]  W. Kraus,et al.  Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. , 2009, JAMA.

[35]  W. Kraus,et al.  Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. , 2009, JAMA.

[36]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[37]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[38]  Gissi-Hf Investigators Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[39]  R. Ferrari,et al.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[40]  H. Rugo,et al.  The cardiac safety of trastuzumab in the treatment of breast cancer , 2010, Expert opinion on drug safety.

[41]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.